Introduction
Acute myeloid leukemia (AML) is characterized by malignant proliferation of leukemic cells ultimately resulting in a suppression of the normal hematopoietic system. 1 Several factors contribute to the growth advantage of the malignant counterpart including the autonomous proliferation and autocrine production of cytokines by these cells, such as granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), interleukin-1 (IL-1) and IL-6.
2-4 IL-6 is a pleiotropic cytokine that can spontaneously be secreted by AML cells in vitro. 2 Binding of IL-6 to the receptor results in dimerisation of the gp130 signal transducing chain and consequently the recruitment of the tyrosine kinases JAK1, JAK2 and Tyk2 to the receptor complex. 5, 6 Upon phosphorylation, signal transducer and activator of transcription (STAT) 3 and to a lesser extend STAT1 are recruited to the receptor complex, phosphorylated on a tyrosine residue (Y705), allowing dimerisation of two STAT molecules via a conserved SH2 domain. 7 Besides activation of STATs, at least two other signaling pathways are also activated by IL-6. The extracellular regulated kinase (ERK) pathway is activated through binding of SHP2 to the receptor complex, 8 whereas
Correspondence: E Vellenga, University Hospital Groningen, Department of the P13K/AKT pathway is activated by the coupling of the Gab family adapter proteins to the gp130 receptor chain. 9, 10 Different STATs have been shown to be spontaneously tyrosine phosphorylated in AML cells. [11] [12] [13] In 30% of AML cases spontaneous STAT3 activation is noticed which is due to the autocrine production of IL-6.
Recently, a family of cytokine-inducible inhibitors of signaling has been identified that downregulate the JAK/STAT signaling pathway.
14, 15 The proteins of this family, including cytokine-inducible SH-2 containing protein (CIS) and suppressor of cytokine signaling (SOCS)/JAK-binding protein (JAB)/STAT-induced STAT Inhibitor (SSI) proteins, are relatively small proteins containing SH2 domains which can interact with JAKs, thus preventing the activation of STATs. Specifically, SOCS1 and -3 are implicated in the downregulation of the IL-6 induced activation of STAT3. [16] [17] [18] Transforming growth factor ␤1 (TGF-␤1) is a member of the TGF superfamily of proteins, also comprising of bone morphogenetic proteins (BMPs), activins and inhibins. TGF-␤1 exerts its effects by binding to its receptor (TGF-␤ receptor type II, T␤RII) which results in recruitment of a second receptor chain (TGF-␤ receptor type I, T␤RI). Heterodimerisation of the receptor chains leads to phosphorylation of T␤RI, resulting in activation of its intrinsic kinase activity. SMAD2 and -3 are subsequently phosphorylated by the activated T␤RI, leading to their association with SMAD4 and translocation to the nucleus where the SMAD2, -3, -4 complex initiates gene transcription of TGF-␤1-responsive genes. 19, 20 In hematopoietic cells, the main function of TGF-␤1 is to regulate cell proliferation by inducing growth arrest in the GO/G1 phase of the cell cycle. [21] [22] [23] [24] The exact mechanism of the cell cycle arrest is not fully understood but might depend on the upregulation of cyclin-dependent kinase inhibitors such as p15, p16, p25 and p27. [25] [26] [27] TGF-␤1 is produced by bone marrow stroma cells as well as by hematopoietic precursor cells, suggesting an important role for TGF-␤1 in controlling the proliferation of these cells. Indeed, the addition of anti-TGF-␤1 neutralizing antibodies to the cell culture system increased the proliferative capacity of precursor cells.
The effects of TGF-␤1 on AML cells is less well defined, both inhibitory and stimulatory effects on AML blasts have been described. The product of the chromosomal translocation (3:21), AML 1/Evi-1, present in 5-10% of AML cases has been described to interact with SMAD3 and thereby blocking the growth inhibitory effect of TGF-␤ in these cells. 28 Occasionally, a stimulatory effect of TGF-␤ has been observed, but these effects were the result of an autocrine induction of growth factors by TGF-␤, rather than a direct stimulatory effect of TGF-␤. 29 In non-hematopoietic cells it has been demonstrated that TGF-␤ might induce apoptosis which could in part be prevented by prestimulation of the cells with IL-6. The protective effect of IL-6 was linked to the STAT3 and P13K/AKT signaling routes. 30, 31 Activation of a caspase3-like activity by TGF-␤1 treatment has been described, although the molecular link between both phenomena is currently unclear. 30, 31 In view of these findings we questioned whether TGF-␤1 might also modulate the IL-6-mediated signaling in hematopoietic cells, especially with regard to the STAT3 phosphorylation. The results demonstrate that treatment of AML blasts with TGF-␤1 results in a reduced IL-6-induced STAT3 tyrosine phosphorylation in 10% of the AML cases investigated. The attenuating effect of TGF-␤1 in these cases was caused by an apoptotic process linked to caspase3 activation, resulting in degradation of JAK kinases as well as caspase-independent processes resulting in a reduced JAK1 phosphorylation upon IL-6 stimulation. It is shown that A549 epithelial cells respond to TGF-␤1 with the induction of SOCS1 and -3 mRNA as well as SOCS1 protein, suggesting a role for this inhibitory molecule in the attenuated IL-6-mediated JAK1 phosphorylation in these cells. In AML blasts, however, no such upregulation could be demonstrated.
Methods

Patient population and isolation of AML cells
Peripheral blood cells from patients with AML were studied after informed consent. AML blasts were isolated by densitygradient centrifugation as described. 32 The cells were cryopreserved in aliquots of 20 to 50 × 10 6 cells/ml in 10% dimethylsulfoxide (DMSO; Sigma, St Louis, MO, USA) and 10% fetal bovine serum (FBS; Life Technologies, Breda, The Netherlands), employing a method of controlled freezing and storage in liquid nitrogen. After thawing, T lymphocytes were depleted by 2-aminoethylisothioronium bromide (AET)-treated sheep red blood cell (SRBC) rosetting. The cell population consisted of more than 98% AML blasts as determined by May-Grü wald-Giemsa staining. Fluorescence-activated cell sorting (FACS) analysis showed Ͻ1% CD3 (Becton Dickinson, Sunnyvale, CA, USA)-positive cells.
Cell culture, reagents and antibodies
AML blasts were cultured at 37°C at a density of 2 × 10 6 /ml in RPMI 1640 media (Biowhittaker, Verviers, Belgium) supplemented with 100 U/ml penicillin, 100 g/ml streptomycin and 10% FBS. A549 epithelial cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and grown in RPMI 1640 media supplemented with 10% FBS and antibiotics. Subconfluent cultures were used and serumstarved 16 h prior to stimulation. Human recombinant IL-6 (a generous gift from Dr SC Clark, Genetics Institute, Cambridge, MA, USA) was used at a concentration of 10 ng/ml. TGF-␤1 was obtained from R&D Systems (Abingdon, UK) and used at a concentration of 500 pg/ml. VP16 was obtained from TEVA pharma BV (Mijdrecht, The Netherlands) and used at a concentration of 5 g/ml. Antibodies against STAT3 (C-20 and K-15), ERK1, PKB, SOCS1, SOCS3 and SMAD3 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), antibodies against phosphorylated STAT3 (Tyr705) and ERK1/2 (Thr202, Tyr 204) were obtained from New England Biolabs (Beverly, MA, USA). Antibodies against JAK1, -2 and Tyk2 were obtained from Upstate Biotechnology (Lake Placid, NY, USA) and an antibody against dual tyrosine phosphorylated JAK1 (Y1022, Y1023) was purchased from Biosource (Nivelles, Belgium). HRP-labelled secondary antibodies were from DAKO (Glostrup, Denmark). The pan-caspase inhibitor Z-VAD-fmk and the proteasome inhibitor MG-123 were purchased from Biomol (Plymouth Meeting, PA, USA) and used at concentrations of 50 m each. The caspase3 substrate Ac-DEVD-pNA was obtained from Calbiochem (La Jolla, CA, USA).
Preparation of protein extracts and Western blotting
Cells were plated in 12-well culture plates, stimulated, washed and collected in PBS. For total cell extracts, cells were lysed in Laemmli sample buffer and boiled for 5 min prior to separation on SDS-polyacrylamide gels. Nuclear extracts were prepared, as described previously, according to the rapid Dignam method. 33 The proteins were transferred to PVDF membrane (Millipore, Bedford, MA, USA), blocked with TBS buffer containing 0.1% Tween-20 and 5% non-fat milk prior to incubation with antibodies, diluted in TBS containing 5% bovine serum albumin. Binding of each antibody was detected by HRP-labelled secondary antibodies using enhanced chemiluminesence (ECL) according to the manufacturer's recommendations (Amersham Life Sciences, Buckinghamshire, UK). When using phosphospecific antibodies, gels were run in duplicate to check for equal amounts of protein in the samples.
Electrophoretic mobility shift assay
Nuclear extracts were prepared, as described previously, according to the rapid Dignam method. 33 A double-stranded synthetic oligo comprising a consensus Smad binding element (SBE) (upper strand: 5Ј-AGTATGTCTAGACTGA-3Ј) was 
Caspase3 assay
5 × 10 6 cells were stimulated for the indicated time and subsequently lysed in 100 l lysisbuffer (10 mm Tris, 10 mm NaH 2 PO 4 /NaHPO 2 , 130 mm NaCl (pH 7.5), 1% Triton-X-100). One hundred l cleared lysate was added to 100 l assay buffer (20 mm Hepes (pH 7.5), 20% glycerol, 4 mm DTT) containing 10 g Ac-DEVD-pNA. Enzymatic conversion was measured using an automated microplate reader set at 37°C with a wavelength of 405 nm during 60 min with read intervals of 1 min. The increase in absorbance during the linear portion of the obtained curves was calculated and used as arbitrary units of caspase3 activity.
Annexin V and propidium iodide assay
After stimulation, 1 × 10 6 cells were washed in PBS and stained with annexin V-FITC and propidium lodide, using an annexin V/propidium iodide staining kit, according to the instructions of the manufacturer (Immune Quality Products, Groningen, The Netherlands). Stained cells were analyzed by flow cytometry.
RT-PCR
After stimulation, total RNA was extracted from 1 × 10 6 A549 cells using Trizol reagent (Life Technologies) according to the manufacturer's instructions. Three g RNA was reverse transcribed using random hexamer priming in a volume of 20 l with 200 units reverse transcriptase (Life Technologies). PCR was performed in duplicate using standard procedures with 1 l of cDNA and primers for beta-2-microglobulin, SOCS1 and SOCS3 as previously described. 34 After the indicated number of cycles, 10 l aliquots of the reactions were run on 1.2% agarose gels and stained with ethidium bromide.
Results
STAT3 tyrosine phosphorylation is reduced by TGF-␤1 pretreatment of AML cells
AML blasts (n = 40) were cultured for 20 h with 1 ng/ml TGF-␤1 and subsequently stimulated for 15 min with IL-6 (20 ng/ml). Whole cell extracts were blotted and probed with antibodies against tyrosine phosphorylated STAT3 and STAT3 protein. In 40 AML cases studied, four cases showed a reduction of IL-6-induced STAT3 tyrosine phosphorylation (10%). Figure 1a shows two representative samples. In the case of AML No. 1, TGF-␤1 treatment resulted in a reduced tyrosine phosphorylation induced by IL-6, while in AML No. 2 TGF-␤1 did not affect the IL-6-induced STAT3 tyrosine phosphorylation. The reduction of tyrosine phosphorylation in the corresponding AML cases was also reflected in a reduced binding of STAT3 to a STAT3 binding element as determined by gelshift assays (data not shown). To investigate the time dependency of the observed effect of TGF-␤1 pretreatment, two AML cases were incubated with TGF-␤1 for different time points and subsequently stimulated with IL-6 for 15 min. Figure 1b shows that a treatment with TGF-␤1 for a long period was required to achieve the reduced STAT3 tyrosine phosphorylation. Probing the same extracts as in Figure 1a of AML No. 1 with an antibody against STAT3 demonstrated that the reduction in tyrosine phosphorylation is not due to a decreased STAT3 protein expression in these cells. To demonstrate the specificity of the effect, the ERK and PKB signaling cascades were studied. As shown in Figure 1c , ERK 1/2 phosphorylation upon IL-6 stimulation was not affected by TGF-␤ pre-treatment. No phosphorylated PKB could be demonstrated. However, when the same extracts were blotted against PKB protein as a control for equal gel loading, a reduction of PKB protein was observed upon TGF-␤1 treatment.
TGF␤ induces SMAD3 translocation in all AML blasts
Since TGF-␤1 did not reduce IL-6-induced STAT3 tyrosine phosphorylation in most of the cases, it was investigated whether these cells could respond to TGF-␤1. AML blasts (n = 8) were stimulated for 45 min with TGF-␤1 and nuclear extracts were prepared. Figure 1d shows the nuclear translocation of SMAD3 in the cases of AML No. 1 and AML No. 2. In addition, the binding of SMAD3 and-4 was analyzed in an EMSA assay using a SBE as a probe. It is shown in Figure 1d that the EMSA results confirmed the Western blot. All AMLs investigated showed similar results indicating that the differential effects on STAT3 tyrosine phosphorylation were not Leukemia ) were prepared with or without TGF-␤1 stimulation for 45 min, Western blotted and probed for SMAD3 (nuclear translocation). The same extracts were used in an EMSA using a SBE as probe.
caused by a defect in TGF-␤1-induced SMAD3 activation and nuclear transfer.
Reduction of STAT3 phosphorylation coincides with a reduction of JAK kinases
To investigate the mechanism causing the TGF-␤1-mediated decrease in IL-6-dependent STAT3 tyrosine phosphorylation, the expression of the different JAK kinases involved in STAT3 activation was examined. Whole cell extracts from blast cells of AML No. 1 with or without TGF-␤1 pretreatment were blotted against JAK1, JAK2 and Tyk2, all known to be activated by IL-6. The results in Figure 2 (lanes 1 to 4) clearly show that JAK1, -2 and Tyk2, protein levels were all decreased upon TGF-␤1 treatment, as was the case for PKB protein levels. No decrease in JAK kinase protein levels was observed in the AML cases that did not respond to TGF-␤1 with a diminished IL-6-induced STAT3 tyrosine phosphorylation (data not shown). The reduction in JAK1, JAK2 and Tyk2 expression in the responding cases strongly correlates with the observed reduction in IL-6-induced STAT3 tyrosine phosphorylation.
TGF-␤1 induces apoptosis in the responding AML cells
Because apoptosis induction by TGF-␤1 has been described, 30, 31, 35, 36 we investigated whether this might be the case in the responding patients. Blast cells of AML No. 1 were cultured for different time periods in the presence of TGF-␤1 and caspase3 activity was measured. Caspase3 was chosen because of its key role in many apoptotic processes. The Apoptosis induction by TGF-␤1 and VP16 results in reduced JAK protein levels, which can be rescued by the pan-caspase inhibitor Z-VAD-fmk. Cells from AML No. 1 were seeded in 12-well plates, pretreated with TGF-␤1 or VP16 (5 g/ml) with (lanes 7-12) or without (lanes 1-6) Z-VAD-fmk (50 m) for 20 h and subsequently stimulated for 15 min with IL-6. Total cell lysates were Western blotted and probed with antibodies against JAK1, JAK2, TYK2, tyrosine phosphorylated STAT3 (pY STAT3) and STAT3. Band intensities of phosphorylated STAT3 and total STAT3 were quantified and fold induction was calculated relative to the unstimulated sample. results in Figure 3a clearly show that, although there is a substantial peak in caspase3 activity in the absence of TGF-␤1, TGF-␤1 enhances the spontaneous caspase3 activity approximately two-fold. No increase in caspase3 activity was observed in AML blasts not responding to TGF-␤1 with respect to a reduced IL-6-induced STAT3 tyrosine phosphorylation (data not shown). In addition, to further underscore the apoptotic process, cells from AML No. 1 were stained with annexinV and propidium iodide after TGF-␤1 treatment. In agreement with the caspase3 activation by TGF-␤1, the same cells also became annexinV and propidium iodide positive after 20 h of TGF-␤1 treatment (Figure 3b ).
VP16-induced apoptosis causes the same phenotype as TGF-␤1 induced apoptosis which is not related to proteasome activation
To test the hypothesis that the induction of apoptosis by TGF-␤1 might be responsible for the decrease of JAK kinases and the concomitant reduction in STAT3 phosphorylation, cells from AML No. 1 were also treated with VP16 as an alternative way to induce apoptosis. The concentration of VP16 used in the experiment (5 g/ml) caused a similar degree of apoptosis as observed with TGF-␤1 treatment, as determined by annexinV and propidium iodide staining (data not shown). After a treatment period of 20 h with VP16, the cells were stimulated with IL-6 and whole cell extracts were made and blotted against JAK1, JAK2, Tyk2, tyrosine phosphorylated STAT3 and STAT3 protein. As depicted in Figure 2 , lanes 5 and 6, the IL-6-induced STAT3 phosphorylation was reduced upon VP16 treatment. In addition, reduced JAK1, -2 and Tyk2 protein levels were observed. In contrast, STAT3 protein levels were not affected by VP16 treatment. These observations strongly suggest that apoptosis induction results in the downregulation of JAK kinase protein levels, which could contribute to a reduced IL-6-induced STAT3 activation.
Since proteasome activity might be involved in the degradation of specific proteins, 37 we investigated whether proteasome activation is involved in the selective breakdown of JAKs and PKB. A specific inhibitor of the 28S proteasome (MG132) was used to investigate this possibility. However, when AML blasts were incubated with MG132, an increase in degradation of JAK kinases and PKB was observed even in the absence of TGF-␤1 or VP16, which was associated with an elevated number of apoptotic cells (data not shown). In view of these findings it is excluded that the proteasome pathway is involved in the degradation of JAK kinases or PKB by TGF-␤1 or VP16.
Caspase activity is not solely responsible for the decreased STAT3 phosphorylation
The observation that caspase3 is activated in response to TGF-␤ treatment prompted us to investigate the relation between caspase activity and protein degradation. A pan-caspase inhibitor (Z-VAD-fmk) was used to block the caspase activity while incubating the blast cells with TGF-␤. The concentration of Z-VAD-fmk used was shown to completely block the TGF-␤1-or VP16-induced apoptosis as determined by annexinV and propidium iodide staining (data not shown). The results in Figure 2 , lanes 7 to 12, clearly show that TGF-␤1-or VP16-induced JAK1, JAK2 and Tyk2 degradation could be blocked by the caspase inhibitor, supporting the idea that apoptotic processes are responsible for the degradation. However, whereas the VP16-mediated reduction of IL-6-induced STAT3 tyrosine phosphorylation was almost totally rescued by blocking the degradation of JAKs (Figure 2, lanes 11 and 12) , a substantial inhibitory effect of TGF-␤1 treatment on the IL-6-mediated STAT3 phosphorylation was still present (Figure 2,  lanes 9 and 10) . These results indicate that other, caspase unrelated mechanisms must also contribute to the decreased IL-6-induced STAT3 tyrosine phosphorylation upon TGF-␤1 treatment.
TGF␤ treatment inhibits JAK1 phosphorylation
To selectively study the effect of TGF-␤1 on STAT3 tyrosine phosphorylation independently of the apoptotic process, the TGF-␤1 and IL-6 responsive epithelial cell line A549 was used. Pretreatment of A549 cells with TGF-␤1 resulted in a reduced IL-6-mediated STAT3 tyrosine phosphorylation which was independent of apoptosis, as determined by the absence of caspase3 activity in the treated cells (data not shown). As depicted in Figure 4a were unaffected by TGF-␤1 treatment in these cells. Because JAK1 is described to be the primary JAK kinase activated upon IL-6 stimulation, 38,39 the phosphorylation status of JAK1 was studied. Cells from AML No. 1, cultured in the presence of Z-VAD-fmk to prevent apoptosis, and A549 cells were incubated with or without TGF-␤1 for 20 h and subsequently stimulated with IL-6 for 5 min. Tyrosine phosphorylated JAK1 was detected using a phosphospecific JAK1 antibody. Figure 4b clearly shows that IL-6-induced JAK1 phosphorylation is almost completely abolished by TGF-␤1 treatment in both cell types.
Suppressor of cytokine signaling (SOCS)1 and SOCS3 mRNA and SOCS1 protein is upregulated by TGF-␤1 in epithelial cells but not in AML cells
In view of the time-dependent effect of TGF-␤1 pretreatment we questioned whether inhibitory proteins might be induced by TGF-␤1 that interfere with the IL-6-mediated STAT3 phosphorylation. Figure 5a shows that SOCS1 and -3 mRNA levels are clearly upregulated upon TGF-␤1 stimulation in A549 cells. Whereas the mRNA level for SOCS3 is down to basal level within 4 h, the level for SOCS1 is still elevated after 8 h of TGF-␤1 treatment. The increase of SOCS1, mRNA is also reflected in the upregulation of SOCS1 protein in A549 cells (Figure 5c ). In contrast to SOCS1, SOCS3 protein levels are not induced by TGF-␤1, despite the induction of SOCS3 mRNA. However, when stimulating cells from AML No. 1 with TGF-␤1 in the presence of the caspase inhibitor Z-VADfmk to block apoptosis, no upregulation of SOCS1 and -3
Figure 5
TGF-␤1 treatment results in SOCS1 and -3 mRNA upregulation in A549 cells but not in AML cells. RT-PCR analysis of RNA extracted from A549 cells (a) or blast cells from AML No. 1 in the presence of Z-VAD-fmk (b). cDNA was PCR-amplified using primers for SOCS1 (upper panels), SOCS3 (middle panels) and beta2-microglobulin as a control for equal cDNA amounts (lower panels). In A549 cells, 28, 26 and 20 cycles were performed for SOCS1, SOCS3 and beta2-microglobulin, respectively. In the AML case, 25, 25 and 18 cycles were performed for SOCS1, SOCS3 and beta2-microglobulin, respectively. PCRs were done in duplicate and repeated at least three times. Results of one representative experiment are shown. (c) Western blot of total cell extracts of A549 cells treated with TGF-␤1 and IL-6. Blots were probed with antibodies against SOCS1 and -3 and actin. mRNA was observed. These results indicate that different mechanisms of downregulating the IL-6-induced STAT3 phosphorylation exist in the two cell types.
Discussion
TGF-␤1 is well known for its key role in the regulation of proliferation and differentiation of hematopoietic cells whereby its growth inhibitory function is the most pronounced. 22, 24, 40 On the other hand, factors like IL-6 play an equally important role in the maintenance of the renewing pool of hematopoietic progenitor cells. 41, 42 In the case of AML, the equilibrium between both positive and negative regulating factors might be disturbed, leading to a disruption in the negative control of cell proliferation. 43 The present study indicates that in a subset of AML blasts TGF-␤1 treatment causes apoptosis, resulting in degradation of JAK kinases involved in IL-6 signal transduction, as well as an apoptosis-unrelated event leading to a diminished JAK1 phosphorylation upon IL-6 stimulation.
Apoptosis induction by TGF-␤ has been demonstrated in non-hematopoietical cells like Hep-3B cells, 30 which could in part be blocked by IL-6 due to the activation of the PI3K signaling route. 10 In hybridoma cells, another member of the TGF superfamily, BMP2, was capable of inducing apoptosis which was linked to the activation and phosphorylation of TAK1 and p38 and independent of STAT3, 44 whereas in B lymphocytes, TGF␤-induced apoptosis was due to the activation of a new aspartyl-protease that could totally be inhibited by the caspase inhibitor BD-fmk and slightly by DEVD-fmk. 38 Recently, it has been shown in Burkitt lymphoma cells that TGF-␤1 could induce apoptosis in a caspase8-dependent manner which could be blocked by the caspase inhibitor Z-VAD-fmk. 36 In the AML cases under investigation in this study, it was shown that the TGF-␤1-and VP16-induced apoptotic process was caspase-dependent resulting in the selective degradation of JAK and PKB proteins without affecting the ERK pathway. The degradation of the JAK proteins was shown to be able to disrupt the IL-6 signaling, resulting in an attenuated STAT3 tyrosine phosphorylation. The degradation of the proteins was not related to the proteasome pathway. This was somewhat surprising in view of the recent finding by Daino et al, 37 demonstrating that the proteasome pathway can be an important pathway for the selective degradation of STAT3. In their study, exogenous-added ubiquitin degraded STAT3 protein resulting in a reduced STAT3 phosphorylation without affecting the ERK protein expression and phosphorylation. This process could totally be inhibited by the selective blocker MG132. However, in AML, MG132 did not inhibit the STAT3 degradation but promoted the apoptotic process and even the degradation of STAT3.
In contrast, the pan-caspase inhibitor Z-VAD-fmk inhibited the degradation of JAK and PKB proteins resulting in part in a restored IL-6-mediated STAT3 signaling. Similar to the proteasome-mediated breakdown of specific proteins described by Daino et al, 37 we find in AML a distinct selectivity in protein degradation in view of the effects on STAT3 and ERK protein expression. Whether the specific degradation of JAKs and PKB is caused by caspase-related enzymatic activity in AML cells directly, or by another phenomenon occurring as a result of the activation of caspases, is at present unknown. It could be speculated that the reduction of JAK and PKB protein expression is merely the result of an impaired production of these proteins caused by the ongoing apoptotic processes in these cells. This could then result in a reduced expression after 20 h of TGF-␤1 treatment because of the relative high turnover rate of at least the JAK kinases. 41 The reduction of proteins involved in cell cycle progression and survival might be an important cellular mechanism to support the apoptotic process. However, despite the prevention of TGF-␤1 and VP16-induced apoptosis and subsequent JAK protein degradation by the caspase inhibitor, a reduced IL-6-mediated STAT3 tyrosine phosphorylation after TGF-␤1 treatment was still present suggesting that additional factors must contribute to the attenuation of the IL-6 STAT3 signaling pathway by TGF-␤1. This was further supported by the finding that in epithelial cells TGF-␤1 treatment also reduced the IL-6-induced STAT3 tyrosine phosphorylation apparently without the induction of apoptosis. It appeared that the reduced IL-6-mediated STAT3 activation was associated with a reduced JAK1 phosphorylation, suggesting a mechanism involving either upregulation of specific phosphatases or inhibition of the JAK signaling by the induction of STAT-specific inhibitors.
A similar inhibition of cytokine-induced STAT activation by TGF-␤1 has been described in T cells. 32 This study describes the inhibition of IL-12-induced JAK2 and Tyk2 phosphorylation by TGF-␤2, resulting in an inhibition of STAT3 and -4 phosphorylation. The time period of TGF-␤ pretreatment needed to exert the effects, however, are quite different between both studies. In the present study, the TGF-␤1 pretreatment period of 20 h needed to reduce the IL-6-induced STAT3 tyrosine phosphorylation suggests an indirect mechanism of action, possibly the induction of inhibitory proteins like members of the SOCS proteins. Indeed, we demonstrated that TGF-␤1 could induce SOCS1 and -3 mRNA, as well as SOCS1 protein, in the epithelial cell line A549. The cause of the lack of SOCS3 protein induction despite the induction of mRNA for this protein is currently not clear. Possibly, posttranscriptional mechanisms play a role in the induction of SOCS3 protein. Induction of SOCS1 and -3 has been shown to be sufficient to attenuate IL-6 (and other members of the IL-6 family of cytokines)-mediated STAT3 phosphorylation. 5, 15, 16 The exact mechanism of inhibition is not fully defined, but it appears that the two SOCS molecules exert their function in different ways. SOCS3 has been described to bind to phosphorylated Tyr759 of the gp130 receptor chain, thus preventing JAK1, -2 and Tyk2 from binding to the receptor complex. 45, 46 In contrast, SOCS1 seems to bind directly to JAK proteins, thus inhibiting their function as activators of STATs. 17 In contrast to the epithelial cell line, however, SOCS1 and -3 mRNA induction could not be demonstrated in the AML case. The cause of this discrepancy between the two cell types is at present unclear. Although the effects of TGF-␤1 on the JAK1 phosphorylation is the same in both cell types, the mechanisms causing this phenomenon are possibly different or related to differences in kinetics at the post-transcriptional level of SOCS expression. 47 Recently, the protein tyrosine phosphatase PTPaC has been implicated in the downregulation of IL-6-induced JAK1 and subsequent STAT3 tyrosine phosphorylation. 48 Whether this phosphatase is a possible candidate for the observed attenuated JAK1 phosphorylation in the AML cells upon TGF-␤1 treatment is currently under investigation.
It is intriguing that only a small percentage (10%) of the AML cases investigated responds to TGF-␤1 with the induction of apoptosis. One could speculate about the question whether the induction of apoptosis by TGF-␤1 is a normal response of hematopoietic cells and abnormal for the AML case. It seems reasonable to assume that the observation that the majority of AML cases do not respond to TGF-␤1 is in fact Leukemia a reflection of the malignant phenotype of these cells. The inability to respond to TGF-␤1 of malignant cells is possibly one way to encompass the normal growth inhibition necessary to maintain a balanced production of hematopoietical cells.
In summary, the results demonstrate that TGF-␤1 is able to attenuate IL-6-induced STAT3 phosphorylation in 10% of AML blasts, which is in part caused by the induction of apoptosis in these cells. The apoptotic process, mediated by caspase activity, causes a selective degradation of some signaling proteins involved in cell survival. The cause of the caspase-independent attenuation of JAK1 phosphorylation by TGF-␤1 treatment in the AML cells remains unclear and is currently under investigation.
